364. Deputy Marie Sherlock asked the Minister for Health the name of each cancer specific drug currently being administered with the support of private insurance in acute hospitals. [66175/26]

380. Deputy Marie Sherlock asked the Minister for Health the name of each non cancer specific drug that is being administered with the support of private insurance in acute hospitals in 2026. [66184/26]

382. Deputy Marie Sherlock asked the Minister for Health the number of non cancer specific drugs being administered with the support of private insurance in acute hospitals for each of the years 2019 to date in 2026. [66181/26]

386. Deputy Marie Sherlock asked the Minister for Health the number of cancer specific drugs being administered with the support of private insurance in acute hospitals for each of the years 2019 to date in 2026. [66177/26]

I propose to take Questions Nos. 364, 380, 382 and 386 together.

As Minister for Health, I am responsible for the legislative framework governing the private health insurance market in Ireland. This is a voluntary market that operates under the core principles of community rating, open enrolment, lifetime cover and minimum benefit.

Under the Health Insurance Act 1994 (Minimum Benefit) Regulations 1996, insurers are required to provide a minimum level of cover to every insured person, regardless of the policy they hold. Private health insurers operate as commercial entities within a competitive market, and where a procedure or service is not designated as a minimum benefit under the Regulations, insurers may determine themselves whether to include it on particular plans.

Decisions regarding medicines funded under private health insurance policies outside the Regulations are commercial matters for the insurers concerned. Beyond the scope of these Regulations, I have no statutory role in the commercial decision-making of private health insurers.